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Extra-abdominal desmoid tumors are a significant cause of morbidity in patients with familial adenomatous polyposis syndrome.
Understanding of the basic biology and natural history of these tumors has increased substantially over the past decade.
Accordingly, medical and surgical management of desmoid tumors has also evolved. This paper analyzes recent evidence pertaining
to the epidemiology, molecular biology, histopathology, screening, and treatment of extra-abdominal desmoid tumors associated
with familial adenomatous polyposis syndrome.
1. Introduction
Desmoid tumors (DTs), also known as aggressive fibro-
matosis, are fibroblastic neoplasms which are often locally
aggressive but lack metastatic potential. They may occur
sporadically or in association with familial adenomatous
polyposis (FAP) syndrome. Among individuals with FAP,
desmoids most frequently occur in intra-abdominal and
abdominal wall locations with most arising from the peri-
toneum. These abdominal desmoids range in severity from
indolent, asymptomatic lesions to highly invasive, some-
times fatal tumors. Although less common than abdominal
desmoids and very rarely fatal, extra-abdominal desmoids
are also a significant cause of morbidity in this population.
This paper will review recent developments in the diagnosis,
screening, treatment, and prognosis of FAP-associated extra-
abdominal DTs.
2. Epidemiology of FAP-Associated
Desmoid Tumors
The overall incidence of DTs has frequently been quoted at 2–
4 per million people per year [1, 2]. This estimate is derived
from a 1986 Finnish study which used the pathologic records
of several regional hospitals and their known catchment area
populations to calculate an incidence figure [3]. Recently,
the Dutch national pathology database was analyzed, and
519 total desmoid cases in patients over the age of ten
were identified from 1999 to 2009. There were 480 sporadic
DTs and 39 FAP-DTs. The annual incidence was 3.7 per
million overall [4] consistent with the earlier Finnish study.
The same nationwide study from The Netherlands identified
1400 patients over the age of ten with FAP during the 1999
to 2009 period. FAP-associated DTs (FAP-DTs) made up
7.5% of all DTs, and the relative risk of an FAP patient
developing a DT was over 800-fold higher than the general
population [4]. The Dutch study was limited by the use of
pathologic specimens as many DTs may be identified based
upon history, physical exam, and imaging but not biopsied or
surgically excised especially in the FAP cohort. Additionally,
some individuals with sporadic DTs may have had as yet
undiagnosed FAP. Therefore, FAP-DTs likely constitute more
than 7.5% of all DTs.
A 1994 study of the Johns Hopkins Polyposis Registry
found that 10% (83/825) of FAP patients had desmoids, and
their relative risk of DTs was 852-fold higher than the general
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population [5]. A study of Mayo Clinic data from 1976 to
1999 identified 447 desmoid patients of whom 70 (15.7%)
had FAP [6]. In all of the previouslymentioned studies, intra-
abdominal and abdominal wall desmoids predominated in
the FAP cohorts whereas extra-abdominal desmoids were
most common among sporadic cases. The sites of extra-
abdominal DTs (head and neck, trunk exclusive of abdom-
inal wall, and extremity) do not appear to vary between the
sporadic and FAP-associated desmoid cohorts. Other consis-
tent demographic findings include younger age at DT pre-
sentation among FAP patients, history of abdominal surgery
in abdominal DTs, and reduced female predominance of
DTs among individuals with FAP [4–7]. Although females
develop DTs more frequently than males in both FAP- and
non-FAP-associated disease, the sex predominance is less in
the FAP cohort. Table 1 summarizes the known risk factors
for DT development in FAP patients based upon the previous
cited studies.
3. Desmoid Histology, Cytogenetics, and
Immunohistochemistry
Desmoids usually present grossly as firm, white tumors with
a coarse, trabeculated surface. They may appear to be scar-
like and encapsulated which belies their infiltrative behavior
at the microscopic level. Histologic analysis reveals bland
spindle-shaped cells in a collagenous stroma containing
blood vessels [8]. The cells lack atypia, but the mitotic rate is
variable [8]. Sporadic and FAP-DTs are indistinguishable at
the gross and microscopic levels. Cytogenetic analyses of DTs
(both sporadic and FAP-associated) have shown trisomies of
chromosomes 8 and 20 to be recurrent abnormalities [9].
Trisomy 8 was found to correlate with recurrence in two
separate studies [9, 10]. Immunohistological staining of DTs
is positive for vimentin and variably positive for muscle and
smooth muscle markers [8]. A study of 116 DT samples
(both sporadic and FAP specimens) found only 7 estrogen
receptor-beta-positive tumors, one C-KIT-positive tumor,
and no HER2 or estrogen receptor-alpha-positive tumors
[11]. A subsequent study of 40 desmoids using different
immunohistological techniques found some degree of estro-
gen receptor beta expression in all samples whereas estrogen
receptor alpha expression was absent in all samples [12].
4. Desmoids and the APC Gene Pathway
Mutation of the tumor suppressor Adenomatous Polyposis
Coli (APC) gene was identified as the cause of FAP in 1991
by two different groups working independently [13–16]. The
APC gene is located on the long arm of chromosome 5
(5q21); its product has been implicated in a wide variety
of cellular processes including cell migration, cell adhesion,
chromosome segregation, spindle assembly, apoptosis, and
neuronal differentiation [17]. Despite these many roles, the
classical function of APC in neopalsia is inhibition of the
WNT signaling pathway. WNTs are a family of secreted gly-
coproteins which act as short range ligands in cell signaling.
Table 1: Demographic risk factors for desmoid development
among FAP patients.
Risk Factor Reference
Younger age [4]
Male sex [4]
Intra-abdominal location [4]
Abdominal wall Location [4]
Mutation 3′ of codon 1444 [7]
Previous abdominal surgery [7]
Binding of WNT on the cell surface upregulates the accumu-
lation of beta-catenin in the cytoplasm, and the beta-catenin
molecules subsequently move to the nucleus and activate
WNT pathway transcription factors [18]. The APC gene pro-
duct, located in the cytoplasm, forms a molecular complex
with Glycogen Synthase Kinase 3 (GSK3) and Axin which in
turn binds beta-catenin leading to its subsequent degrada-
tion [19]. The APC pathway is summarized in Figure 1.
Both sporadic and FAP-DTs have been analyzed for APC
and beta-catenin mutations. As expected, most FAP-DTs
show a second somatic mutation of the APC gene [20]. How-
ever, the secondary somatic mutations of the FAP-DTs have
been shown to differ consistently from the secondary somatic
mutations in the colonic polyps from the same individuals
[21]. APC mutations are infrequently found in sporadic
DTs [22] which more frequently demonstrate beta-catenin
mutations [23, 24].
5. Genotype Phenotype Correlations in
FAP-Associated Desmoids
The correlation of genotype with phenotype in FAP-DTsmay
permit more efficient screening strategies, improved treat-
ment regimens, and ultimately targeted therapy of the dis-
ease. A variant of FAP, termed hereditary desmoid disease
was first described by Eccles et al. in 1996 [25]. They reported
100% penetrance of desmoid tumors in a three-generation
kindred with a mutation in the extreme 3′ end of the APC
gene [25]. DTs in this kindred had both extra- and
intra-abdominal involvement. Subsequently, Couture et al.
reported a large French-Canadian kindred with a similar
phenotype and extreme 3′ mutation of the APC gene [26].
This kindred had extensive desmoid disease and attenuated
colonic polyp formation in contrast to classic FAP. These
authors further demonstrated that desmoid tissue from a
member of the kindred had elevated beta-catenin levels [26].
Prior studies of the secondary somatic mutations which
occur in FAP colon polyps revealed that the type and loca-
tion of the somatic mutation were nonrandom and at least
partially determined by the location of the germ-line muta-
tion [21, 27]. The APC gene product contains seven 20 amino
acid beta-catenin degradation repeats (AARs). These repeat
segments permit binding of beta-catenin leading to its
ultimate degradation. The “just right” model of FAP tumori-
genesis proposes that there is an ideal level of beta-catenin
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Figure 1: Model of the WNT/APC/beta-catenin pathway (Adapted from Moon et al. [18].)
binding suitable for polyp progression to colon cancer, and
selective pressure results in nonrandom selection of somatic
mutations with the appropriate number of AARs [27].
Analysis of FAP-DTs by Latchford et al. revealed that 87%
(26/30) of tumors had one allele with no AARs and
preferentially retained a total of two AARs 57% (17/30) [28].
These authors suggested that specific levels of beta-catenin
activity are required by the different tumor types with
desmoids preferentially requiring two AAR segments. A
large Japanese study (86 colorectal tumors, 40 extracolonic
tumors) identified similar associations between AARs and
phenotype. With respect to FAP-DTs, 5 of 6 were found to
have two AARs in the Japanese study [29].
Development of desmoids among individuals with FAP
has been correlated with specific mutations. Early studies
with small numbers of FAP-DTs suggested that mutations
in these patients tended to occur at the 3′ end of the gene
[30, 31]. A 2001 study from Hereditary Colorectal Tumor
Registry in Milan analyzed 809 FAP patients of which 107
(11.9%) developed DTs including 59 extraabdominal cases
[32]. These authors found a 12-fold increased risk of DT
when the APC mutation occurred beyond codon 1444 as
compared with upstream mutations [32]. In a multivariate
analysis, these authors determined that genotype was the
strongest predictor of desmoid development [32]. A 2007
review of the world literature on APC genotype/phenotype
correlation identified ten articles with data on FAP-DTs.
The reviewers concluded that patients with APC mutations
downstream of codon 1400 were at increased risk of desmoid
development [33]. More recently, genotype data have been
incorporated into a desmoid risk scoring system for FAP
patients. Female sex, presence of other extracolonic man-
ifestations, a relative with a DT, and genotype were the
risk factors considered [34]. The authors utilized the risks
identified using this system to guide surgical management.
They advocated use of antiadhesion material, sulindac pro-
phylaxis, and minimally invasive techniques in patients at
increased risk of desmoid formation [34].
6. Gene Expression Profiles of
FAP-Associated Desmoids
APC is a large protein with numerous binding sites and
multiple putative functions. Gene expression profiling is one
strategy which has been used to better understand the com-
plex downstream effects of APC mutations. A critical factor
in gene expression profiling is determination of which tissues
should be compared because genes can only be up- or down-
regulated with respect to a reference specimen. With ref-
erence to DTs, numerous tissue samples have been studied
including FAP-DTs, sporadic DTs, banked reference fibrous
tissue, fibrous tissue from the same patient, adenomatous
tissue from the same FAP patient, and many other banked
histologic specimens. The technical aspects of each study are
beyond the scope of this paper, but some notable findings
merit discussion. The first desmoid gene expression profile
study (2004) compared 12 sporadic DTs with banked normal
fibrous tissue. Notably, the study identified two distinct
groups within the 12 patients based upon gene expression,
but no obvious clinical correlations were evident [35]. A 2006
study analyzed four tumors (2 with APC mutations, 2 with
beta-cateninmutations) using normal fibrous tissue from the
same patients as control. Sixty-nine differentially expressed
genes were identified, of which 33 were upregulated and
36 were downregulated [36]. Interestingly, no differences in
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the profiles of the APC and beta-catenin tissues were identi-
fied. The authors additionally confirmed consistent down-
regulation of insulin-like growth factor-binding protein 6
using reverse transcriptase PCR and Northern blot assays
[36].
A study comparing desmoid samples (both sporadic
and FAP associated) with nodular fasciitis was performed
using 33 DTs and 11 nodular fasciitis specimens. Hierar-
chical clustering revealed distinct gene expression signatures
between the two groups [37]. The authors concluded that
this technology may be useful in diagnostically challenging
cases. Gene expression profiling may also be of prognostic
value as demonstrated by a 2007 study which found that ele-
vated beta-catenin and p53 expression correlated with local
recurrence in a retrospective analysis of 37 DTs (sporadic
versus FAP not specified) [38]. A recent study reported the
results of array comparative genomic hybridization analysis
of 196 DTs (only 5% were FAP-DTs) [39]. Four recurrent
chromosomal abnormalities were identified: loss of 6q, loss
of 5q, gain of 20q, and gain of chromosome 8 [39]. Loss of
5q is likely explained by APC localization to this region. The
other gains and losses suggest avenues of future investigation.
A 2011 study compared sporadic and FAP-DTs using
array comparative genomic hybridization analysis [40]. The
authors analyzed 17 FAP-DTs and 38 sporadic DTs. They
found more copy number abnormalities among the FAP-
DTs than the sporadic DTs. Loss of 6q was common to both
sporadic and FAP-DTs, and the authors believed that further
study of genes in this region may help elucidate desmoid
tumorigenesis [40]. They noted that several known or puta-
tive tumors suppressor genes including ANKRD6, BACH2,
MAP3K7/TAK1, EPHA7, and NLBP/KIAA0776 reside in this
region. As yet, none of these putative tumor suppressors have
been correlated with the downregulated genes identified in
the previously discussed gene expression profile studies.
Another application of gene expression profiling is
analysis of treatment response. A 2010 report compared a
FAP-DT human cell line with a sporadic DT human cell line
using microarray analysis [41]. Doxorubicin-treated cells
from each line were compared with each other and their
untreated controls. Separate in vitro assays had already
shown that the FAP-DT cell line demonstrated greater doxo-
rubicin resistance than the sporadic DT cell line [41]. The
gene expression profiles of the treated cells differed in that the
pro-survival genes netrin 1 and tumor necrosis factor receptor
superfamily member 10c were upregulated in the treated
FAP-DT line and the proapoptotic gene forkhead box L2 was
upregulated in the treated sporadic DT line [41]. Although
this study was preliminary and in vitro, gene expression pro-
filing may ultimately be applicable to prediction of response
to treatment in humans.
7. Desmoid Cell of Origin
As recently as 2000, debate existed as to whether desmoids
were neoplastic or reactive. A 2000 study by Middleton et al.
demonstrated that FAP-DTs were monoclonal [42]. The
authors derived a clonality ratio by assessing X chromosome
inactivation in desmoid samples from 12 female patients.
Although it is now generally agreed that desmoids, both
sporadic and FAP associated, are neoplastic, the cell of origin
has yet to be identified. Recent animal studies suggest that
mesenchymal stem cells (MSCs) are likely candidates and
at minimum contribute to tumor development. Wu et al.
recently demonstrated that MSCs and desmoids had similar
gene expression profiles, and mice deficient in MSCs but
prone to desmoids (mice with an APC mutation and def-
icient MSC production) developed fewer desmoid tumors
while colonic tumor rates were uneffected [43]. In fact,
desmoid development was directly proportional to the num-
ber of MSCs present. Additionally, MSCs with the APC
mutation from heterozygote APCwt/1638N mice produced DTs
when transplanted to immunodeficient mice, but MSCs
without the mutation did not. Furthermore, they found that
MSCs from mice with inducible expression of beta-catenin
(Catnbtm2kem mice) could also induce desmoid-like tumors
when transplanted to immunodeficient mice. Finally, they
showed that these tumors were clonally derived from the
donor MSCs with use of a green florescent protein tag [43].
A 2012 study has further defined the role of mesenchymal
stem cells in FAP-DTs using human tissue. Carothers et al.
analyzed 16 human desmoid specimens and using immuno-
histochemistry found that desmoid tissue expressed MSC
markers but surrounding normal tissue did not [44]. They
next developed a primary desmoid cell line from the human
desmoid tissue. These cells had an immunohistochemical
profile consistent with MSC, and the cells were able to dif-
ferentiate into chondrocytes, osteocytes, and adipocytes con-
firming that they are MSCs [44]. These human desmoids-
derived MSCs were found to have elevated beta-catenin in
their nuclei (similar to desmoid tissue) and demonstrated
upregulation of the Notch and Hedgehog pathways [44].
The aforementioned studies do not definitively prove
that MSCs are the cell of origin in FAP-DTs, but they at a
minimum demonstrate the importance of MSCs in desmoid
development. The association between desmoid develop-
ment and surgical wound healing in patients with FAP has
long been established [45]. Presence of extra-abdominal and
abdominal wall DTs increases the risk of intra-abdominal DT
development at the time of prophylactic colon resection [46].
A recent case report analyzed the individual tumormutations
of a FAP patient with multiple recurrences at the same sur-
gical site. Interestingly, different APC mutations were identi-
fied in the “recurrent” tumors suggesting that these were in
fact new clonal populations and not true recurrences [47].
Based upon the previously noted findings, one can postulate
a model in which secondary somatic mutations develop in
the MSC rich wound healing environment of FAP patients.
This model fits well with the known development of des-
moids after surgical or incidental trauma in the FAP pop-
ulation.
8. FAP Screening and Treatment Guidelines in
relation to Desmoid Treatment
Physicians specializing in the treatment of sarcomas will
rarely be the first to diagnose FAP because desmoids in these
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patients most frequently occur after gastrointestinal man-
ifestations of the disease are evident. Additionally, many
kindreds have been extensively tested, and affected family
members are frequently diagnosed early in childhood. How-
ever, de novomutations may occur, and individuals with FAP
may still initially present with extracolonic manifestations
such as desmoids. A meta-analysis of desmoid risk among
FAP patients identified family history of DT, APC mutation
3′ to codon1399, previous abdominal surgery, and female sex
to be significant risk factors for DTs [48]. The same analysis
found that 80% of FAP-DTs occur before age 40 [48]. Two
other studies have noted that FAP-DTs present at a younger
age in females than males [45, 49]. Practitioners should
therefore suspect FAP in patients with a family history of
desmoids and in young patients presenting with desmoids.
Referral to gastroenterologists, geneticists, and colon and
rectal surgeons experienced in FAP care is critical if the
diagnosis is suspected. Many cancer centers have well estab-
lished multidisciplinary groups and polyposis registries. A
2006 review of screening guidelines recommended careful
postcolectomy follow-up to asses for desmoids as early inter-
vention has anecdotally improved outcome for some [50].
Practical surveillance measures for all FAP patients include
asking them about new masses and examining their body
surface for tumors at each visit.
Other extracolonic manifestations of FAP should be
considered by the clinician treating FAP-DTs. Gastric polyps
were found in 88% of FAP in a 2008 study of 75 consecutive
FAP patients, and gastric cancer rates are increased in this
population [51]. Duodenal and papillary adenomas occur in
50–90% of FAP patients, and there is an overall 5% lifetime
risk of duodenal cancer in FAP patients [52, 53]. Routine
surveillance of the upper gastrointestinal tract with endo-
scopy is therefore recommended [53]. APC is a tumor sup-
pressor gene and is associated with other cancers including
papillary thyroid carcinoma, hepatoblastoma, medulloblas-
toma and other brain tumors, and pancreatic cancer [54].
The associated cancer risks are low (1-2% for each diagnosis)
compared with the 100% risk of colon cancer in untreated
FAP [33, 54]. However, these associated tumors (except
pancreatic cancer) tend to occur at a young age, often before
gastrointestinal manifestations develop. This fact further
emphasizes the importance of genetic testing of at-risk
individuals. Nonmalignant FAP associations include adrenal
tumors, osteomas, congenital hypertrophy of the retinal
pigment epithelium (CHRPE), and dental abnormalities [33,
54]. Most of these nonmalignant entities do not cause signi-
ficant morbidity, and as previously noted DTs are the most
clinically significant nonmalignant extracolonic manifesta-
tion of the disease. Table 2 summarizes the extra-colonic
manifestations of FAP.
9. Evolving Trends in the
Surgical Management of FAP-DTs
The surgical treatment paradigm for DTs in general has
changed substantially over the past decade. Overall, a less
aggressive surgical approach has been adopted by many
Table 2: Extracolonic FAP manifestation (Neiuwenhuis [33] and
Groen [54]).
Extracolonic manifestation
Prevalence in FAP
patients
CHRPE 70–75%
Osteomas and dental abnormalities 70–90%
Upper GI tumors 50–90%
Epidermoid cysts and lipomas 25–50%
Desmoid tumors 15–20%
Adrenal tumors 7–13%
Papillary thyroid cancer 1-2%
Hepatoblastoma 1-2%
Brain Tumors (Medulloblastoma and others) 1-2%
Pancreatic Cancer 1%
centers. In 1989, a large series (131 patients, both sporadic
and FAP-DT) from Memorial Sloane-Kettering was pub-
lished detailing desmoid cases at the institution from 1965 to
1984. Adequacy of surgical margin was found to be the single
most important factor in successful treatment of desmoids
[55]. The authors concluded that “aggressive resection in an
effort to obtain as wide a margin as possible is clearly the sin-
gle most important determinant of successful outcome” [55].
A Mayo Clinic series reporting extra-abdominal desmoid
cases from 1981 to 1989 similarly found a high local recur-
rence rate (9/19) in patients with microscopic residual dis-
ease [56]. In 1999, another report (105 patients with primary
desmoid disease, both sporadic and FAP-DT) from Memo-
rial Sloan-Kettering covering the years 1982–1997 did not
find positive microscopic margin to be predictive of local
recurrence [57]. These later authors recommended against
excessively morbid resections in an effort to obtain wide
margins. In 2003, Gronchi et al. reported a series of 203
consecutive desmoid patients treated over 35 years at a single
institution. They found that microscopic positive margins
did not adversely affect recurrence rates for primary disease
[58]. They recommended function sparing surgery and
resection of all macroscopic disease but avoidance of heroic
attempts at obtaining negative microscopic margins. A
smaller series from the United Kingdom reported the results
of surgery for 32 FAP-DTs including 16 intra-abdominal,
12 abdominal, and 4 extra-abdominal tumors treated from
1994 to 2004. In contrast to some prior reports of abdominal
desmoids in FAP patients, they had no desmoids-related
mortalities and only one patient required long-term par-
enteral nutrition [59]. These authors noted that they had a
high threshold for surgery, and that most intra-abdominal
desmoids at their institution were treated conservatively.
Even more recently, several authors have begun advocat-
ing a wait and see approach to DTs as it has been recognized
that many DTs undergo a prolonged stable phase or even
spontaneous regression. A 1998 article from this journal
reported a series of 17 patients treated nonoperatively, all of
whom had an interval of at least six months without disease
progression [60]. Subsequently, a French report identified
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a subgroup of patients who did well with a wait and see
approach. Only 23 patients were included in the nonoper-
ative group, and there were no strict inclusion criteria [61].
A subsequent, larger study analyzed the results of a routine
front-line conservative approach used to treat both primary
and recurrent desmoids at two institutions [63]. Seventy-
four primary and 68 recurrent tumors were studied. Eighty-
three received no intervention, and 59 received medical
therapy. Overall progression-free survival was 64% at 3 years
and 53% at 5 years. There was not a statistically significant
difference in progression free survival between the no inter-
vention and the medically treated groups [63]. The authors
did not believe that subsequent surgery was compromised by
delay in the patients who progressed. More recently, a study
was performed to identify factors associated with progression
free survival. In a multivariate analysis of 426 sporadic
desmoid tumors, age less than 37, extremity location, and
size greater than 7 cm were associated with progression [65].
Notably, the authors could not determine how to use this
information with respect to surgery versus wait and see. One
could argue that DTs at high risk of progression should be
resected early because conservative treatment is more likely
to fail. On the contrary, perhaps the high-risk group should
be observed because theymay bemore biologically aggressive
and therefore more likely to recur after surgery. This cannot
be answered without prospective data.
Most of the aforementioned studies included few if
any FAP-DTs. There are no studies which show that FAP
associated extra-abdominal desmoids behave differently than
their sporadic counterparts with respect to surgical man-
agement of primary disease. As previously discussed, FAP-
DTs may occur after surgery and trauma. This phenomenon
is presumably related to the wound healing environment
in the setting of germ-line APC mutations. A conservative
approach to intra-abdominal desmoids has long been recom-
mended due to the high morbidity and even mortality noted
in many early studies [64, 66]. Modern studies of FAP-DTs
have shown that resection is surgically safe but recurrence
rates remain high. Consensus for first-line conservative
management is growing [63–65]. The studies referenced in
this section are summarized in Table 3.
10. Medical Treatment of FAP-Associated
Extra-Abdominal Desmoids
Current first-line medical management includes antihor-
monal therapy (specifically tamoxifen) and nonsteroidal
anti-inflammatory drugs (NSAIDs, specifically sulindac,
indomethacin, and more recently celecoxib) [62]. A recent
review of antiestrogen therapy for DTs found that approx-
imately half of patients respond, and response does not
appear to correlate with estrogen receptor status [67]. Fur-
thermore, the desmoid location and FAP status of the patient
do not appear to influence the response [67]. NSAIDs have
shown efficacy against desmoids in numerous studies, but
themechanism of action of these agents is even less clear than
that of antidestrogen therapies [68]. A mouse model of APC-
associated desmoid tumors was found to have elevated levels
of cyclooxygenase-2, andmice treated with a cyclooxygenase-
2 inhibitor had decreased desmoid tumor size [69]. There are
little human data corroborating the effects of prostaglandins
and prostaglandin inhibition on DTs.
Multiple chemotherapeutic agents have shown efficacy
against desmoids including doxorubicin, methotrexate plus
vinblastine, cyclophosphamide plus doxorubicin, and VAC
(vincristine, actinomycin-D, cyclophosphamide) [68, 70].
Interferon alpha has also been used singly and in combina-
tion with some of the aforementioned cytotoxic agents [68].
More recently, targeted biologic agents have been added to
the desmoid treatment armamentarium. Two phase 2 trials
have reported efficacy of imatinib, a tyrosine kinase inhibitor,
in the treatment of desmoids [71, 72]. As previously men-
tioned, C-KIT expression is lacking in most DTs. Analysis
of 124 DTs from 85 patients found that PDGF alpha and
PDGF receptor alpha were expressed in all tumors, but PDGF
beta and PDGF receptor beta were not expressed [73]. The
same authors failed to identify PDGF receptor mutations in
14 analyzed specimens [73]. These data suggest that ima-
tinib’s efficacy against desmoids results from a mechanism
other than direct inhibition of these known tyrosine kin-
ase protooncogenes. Another tyrosine kinase inhibitor, so-
rafenib, has also shown efficacy against desmoids in a
smaller single-institution trial [74]. Finally, a clinical trial
(NCT01265030) of the mammalian target of rapamycin
(mTOR) inhibitor, sirolimus, for the treatment of desmoids
in children and young adults was opened in 2010. The large
number of agents used for DTs clearly indicates that presently
there is lack of consensus with respect to medical manage-
ment of this condition.
11. Conclusion
Understanding of the epidemiology, genetics, molecular and
cellular biology, pathophysiology, and treatment of FAP
related desmoid tumors has improved substantially over the
past decade. Despite these improvements, DTs remain a
major cause of morbidity in the FAP population. A more
conservative surgical approach is presently advocated by
many oncologic surgeons.Medical management is attempted
first for most abdominal DTs, and a wait and see approach
is undertaken for many extra-abdominal DTs. Surgical goals
and techniques are now often less aggressive than in the past.
Recent studies have implicated mesenchymal stem cells as
critical components of desmoid development. Gene expres-
sion profiling has shown promise in elucidating downstream
elements of the WNT/APC/beta catenin pathway. Future
progress in treatment will likely depend upon continued
advances in understanding of basic desmoid biology and
the development of additional targeted therapies for the
treatment of refractory cases.
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